Diabetic gastroparesis
Drug research and approvals for diabetic gastroparesis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 10 studies of diabetic gastroparesis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 5 drug trials for it since 2013.
- Recruiting worldwide: 10
- Trials authorized in Canada: 5
- FDA orphan approvals: 0
- EU medicines: 0
Newest posted first, of 10 recruiting on ClinicalTrials.gov ↗
- Effect of Virtual Yoga in Diabetic Gastroparesis PatientsNCT07717554 · Not applicable · Ohio State University · starts Jul 17, 2026
- Correlation Between Advanced Glycation End Products and Gastric Motility Disorder in Diabetes GastroparesisNCT07324785 · Not reported · Northern Jiangsu People's Hospital · starts Jan 7, 2026
- To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.NCT07287943 · Not applicable · Viral N. Shah · starts Feb 9, 2026
- Laparoscopic Implantation of a Gastric Pacemaker in the Treatment of GastroparesisNCT06661668 · Not reported · Evangelic Hospital Kalk Cologne · starts Jan 1, 2023
- Study of Enhanced Programming Stimulation with the Enterra® Therapy SystemNCT06560307 · Not applicable · Enterra Medical, Inc. · starts Jul 25, 2024
- Washed Microbiota Transplantation for Diabetic GastroparesisNCT06340217 · Not applicable · The Second Hospital of Nanjing Medical University · starts Apr 1, 2024
- Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 DiabetesNCT06046833 · Not applicable · Samita Garg · starts Jan 8, 2024
- Study of Enterra Programming with Nocturnal Cycling in GastropareticsNCT05980455 · Not applicable · Enterra Medical, Inc. · starts Jul 10, 2023
- Gastroparesis Registry 4NCT05846802 · Not reported · Johns Hopkins Bloomberg School of Public Health · starts Sep 20, 2024
Newest first; search them all in Canada trials
| Jul 24, 2019 | Open-label extension study of relamorelin for the treatment of diabetic gastroparesisRelamorelin | AbbVie | Closed |
| Jun 4, 2018 | A 52-week, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of relamorelin in patients with diabetic…Relamorelin | AbbVie | Closed |
| May 14, 2018 | A 46-week, double-blind, placebo-controlled, phase 3 study with a 6-week randomized-withdrawal period to evaluate the safety and efficacy of relamorelin in…Relamorelin | AbbVie | Closed |
| Dec 15, 2017 | A 12-week, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of relamorelin in patients with diabetic…Relamorelin | AbbVie | Closed |
| Dec 4, 2013 | Prucalopride versus placebo in diabetic gastroparesis: randomized placebo-controlled crossover trialPrucalopride | University of Calgary | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA